Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Heron Therapeutics Inc (HRTX) vs SOLAI Limited (SLAI) Price & Performance

Heron Therapeutics IncTrade
SOLAI LimitedTrade

Price performance (Past 24H)

Key statistics

Heron Therapeutics Inc vs SOLAI Limited — how do they compare? Heron Therapeutics Inc trades at $0.32 (market cap $61.47M), while SOLAI Limited trades at $3.72 (market cap $16.69M). The key difference: Heron Therapeutics Inc is far larger — about 3.7× SOLAI Limited's market cap. Which is the better fit depends on your goals.

HRTXSLAI
Market Cap
$61.47M$16.69M
Sector
HealthTechnology
52-Week High
$1.49$26.74
52-Week Low
$0.32$2.74
Enterprise Value
$168.21M$16.33M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Heron Therapeutics Inc

Heron Therapeutics (HRTX) trades at $0.3409, up 3.24% today, but faces bearish technical signals with 18 sell indicators versus 6 buys. The company reported Q2 2026 revenue of $37.7 million but missed earnings expectations with a $0.03 per share loss. Despite strong analyst support (94.7% buy ratings), fundamental challenges persist with negative net income margins and elevated EV/EBITDA of 34.03.

Investment outlook remains cautious due to consistent earnings misses and negative cash flow from operations. The primary opportunity lies in analyst optimism and potential product growth, while risks include ongoing profitability challenges and competitive pressures in the biotechnology sector.

SOLAI Limited

SLAI trades at $3.72 with no recent price movement, showing mixed technical signals despite a bullish overall rating. The company faces severe financial distress with negative profit margins (-134.63% net income margin) and declining revenue, compounded by NYSE delisting proceedings initiated in July 2026. Recent corporate actions include a 7:1 reverse stock split completed in July 2026 and the acquisition of a 51% stake in NEURALAND, signaling strategic shifts amid operational challenges.

The outlook remains highly speculative with significant execution and liquidity risks. While technical indicators suggest potential short-term momentum, fundamental weaknesses and delisting uncertainty create substantial downside risk. Investors should approach with caution given the company's negative profitability and regulatory challenges.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Heron Therapeutics Inc

Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.

Read more on HRTX

About SOLAI Limited

SOLAI focuses on providing innovative AI-driven software solutions. The company leverages artificial intelligence to enhance digital experiences and optimize business processes for various industries.

Read more on SLAI